Comparative Pharmacology
Head-to-head clinical analysis: ARBLI versus CEFIZOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARBLI versus CEFIZOX.
ARBLI vs CEFIZOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.
Cefizox (ceftizoxime) is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition.
10 mg orally once daily.
1-2 g IV/IM every 8-12 hours; maximum 12 g/day for severe infections.
None Documented
None Documented
Terminal elimination half-life of 26 hours (range 20-32 h), supporting once-daily dosing; prolonged in hepatic impairment.
1.7-1.9 hours in adults; prolonged to 15-25 hours in severe renal impairment (CrCl <10 mL/min)
Primarily biliary (>70%) and fecal elimination; renal excretion accounts for <5% of unchanged drug.
Primarily renal (90-95% unchanged via glomerular filtration and tubular secretion); biliary (<1%); fecal (minimal)
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic